MedTrace Logo

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

NCT04262466 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 410

Last updated 2026-03-06

No results posted yet for this study

Summary

Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of brenetafusp in adult participants who have the appropriate HLA-A2 tissue marker and whose cancer is positive for PRAME.

Conditions

  • Select Advanced Solid Tumors

Interventions

DRUG

Brenetafusp

Brenetafusp IV infusions

DRUG

Brenetafusp and pembrolizumab

Brenetafusp and pembrolizumab IV infusions

DRUG

Brenetafusp and chemotherapy

Brenetafusp and chemotherapy IV infusions

DRUG

Brenetafusp and monoclonal antibodies and chemotherapy

Brenetafusp and a monoclonal antibody therapy and chemotherapy

DRUG

Brenetafusp and tebentafusp

Brenetafusp and tebentafusp IV infusions

DRUG

Brenetafusp and bevacizumab

Brenetafusp and bevacizumab IV infusions

DRUG

Brenetafusp and kinase inhibitors

Brenetafusp and oral kinase inhibitors

Sponsors & Collaborators

  • Immunocore Ltd

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-25
Primary Completion
2026-10-31
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Austria
  • Belgium
  • Brazil
  • Canada
  • France
  • Germany
  • Ireland
  • Italy
  • Netherlands
  • New Zealand
  • Poland
  • South Korea
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04262466 on ClinicalTrials.gov